Shandraw Capital
Shandraw Capital is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Shandraw Capital.
Shandraw Capital is a company.
Key people at Shandraw Capital.
Key people at Shandraw Capital.
Shandraw Capital is an investment firm led by Cody Shandraw, emphasizing data-driven decision making, hands-on leadership, and alignment of operations with long-term strategic goals.[5] The firm operates within the psychedelics, neurowellness, and mental health sectors, investing in early-stage companies, non-traditional ventures, and related real estate opportunities like clinical spaces for psychedelic treatments.[1][2][3][5][6]
Associated with Shandraw's broader activities through funds like Phyto Partners and Ambria Capital, the focus includes businesses in brain health, psychedelics for mental health disorders, and infrastructure such as Healing REIT for MDMA therapy clinics near VA hospitals.[1][2][3] This positions Shandraw Capital to support entrepreneurs improving lives via innovative therapies, with a track record of bullish investments amid regulatory shifts in psychedelics.[6]
Cody Shandraw, the key figure behind Shandraw Capital, emerged as a serial entrepreneur in the psychedelics and mental health investment space.[3][4][6] His involvement deepened around 2019 when he joined Ambria Capital as Managing Partner, overseeing due diligence in early-stage psychedelics companies and non-traditional opportunities; Ambria, founded in 2018 by Michael Sobeck, targets mental health tech innovations.[2]
Shandraw co-manages Phyto Partners, launched with Larry Schnurmacher, focusing on neurowellness and brain health businesses.[1] A pivotal moment came with co-founding Healing REIT in 2023 alongside Zakovich and Daniel Carcillo, securing initial $250K from Phyto and $1M seed funding to acquire clinic spaces for psychedelic treatments, marking a shift toward real estate enabling psychedelic medicine.[3] This evolution reflects Shandraw's progression from investor to ecosystem builder in psychedelics.[4][6]
Shandraw Capital rides the psychedelics renaissance, fueled by FDA breakthroughs like MDMA for PTSD and growing acceptance of neurowellness therapies amid mental health crises.[1][2][3][6] Timing aligns with regulatory progress, veteran-focused treatments near VA sites, and demand for harm reduction/education, positioning it to capitalize on market forces like decriminalization and clinical expansion.[2][3]
By funding both biotech and enabling real estate, it influences the ecosystem through infrastructure for therapies, bridging finance with practical deployment and accelerating adoption in underserved areas like PTSD care.[3] This holistic approach amplifies impact in a sector blending biotech, real estate, and tech innovations.[1][2]
Shandraw Capital is poised for growth as psychedelics gain mainstream traction, with Healing REIT eyeing NYSE listing and a $47M portfolio to support clinic proliferation.[3] Trends like psychedelic legalization, AI-enhanced mental health tech, and veteran health reforms will shape its path, potentially scaling influence via larger funds and public vehicles.[2][3][6]
Expect evolution toward integrated ecosystems—combining capital, real estate, and ops support—driving Shandraw from niche investor to key enabler in neurowellness, much like its data-driven origins promise sustained strategic alignment.[5]
